Clinical Evaluation of Tranilast for Keloid and Hypertrophic Scar.

概要

論文の詳細を見る
Clinical effect and usefulness of Tranilast was evaluated in 35 cases of keloid and hypertrophic scar. Tranilast was given at a dose of 300mg/day for 12 weeks.<BR>In the final over all rating of improvement, safety and usefulness, the result obtained were 66.7% (moderate or better), 82.9%, and 61.3% (moderate or better), respectively.<BR>In detail more than 2 grades improvement of itching and spontaneous pain were seen in more than 40% of the patients, and that of pressure pain was about 30%. More than 2 grades improvement in reduction of enlargement tendency and erythema were about 50% and 30%, respectively. Adverse reactions were reported in 4 cases (11.4%). Most of them were mild digestive symptoms, which recovered after withdrawal or by taking additional medicaments. In clinical laboratory tests, changes in s-GOT, s-GPT and Al-p were seen in two cases (5.7%). But these were not accompanied by clinical symptoms.<BR>From the results of the present study, it is considered that Tranilast is a useful drug for keloid and hypertrophic scar.
日本皮膚科学会大阪地方会の論文